Moors & Cabot’s CareDx CDNA Stock Holding History

Moors & Cabot’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,325	Closed	-$201K	–	895
2025 Q1	$201K	Buy	+11,325	New	+$244K	0.01%	787

Other funds holding CDNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAM

Ophir Asset Management Sydney, Australia $859M AUM 59.08% 1-Year Est. Return

Moors & Cabot's CDNA Position: Q2 2025 in Review

Moors & Cabot sold out of CareDx (CDNA) in Q2 2025, closing a stake of 11,325 shares — an estimated $201K sold.

Moors & Cabot first reported a position in CDNA in Q1 2025 and held it in 1 quarter. The position peaked at $201K in Q1 2025. 197 funds tracked by Wall St. Rank hold CDNA as of Q2 2025.

Moors & Cabot reported no remaining CareDx position as of Q2 2025 after selling out during the quarter.
Moors & Cabot sold 11,325 CareDx shares in Q2 2025, an estimated $201K.
Moors & Cabot first reported a position in CareDx in Q1 2025 and held it in 1 quarter.
Moors & Cabot's CareDx position peaked at $201K in Q1 2025.
197 funds tracked by Wall St. Rank held CareDx as of Q2 2025.

Based on Moors & Cabot's 13F filing for Q2 2025, filed 6 Aug 2025.